New Campaign for Rentschler's 'Facility of the Year'
News Jul 17, 2012
Rentschler has undergone significant expansion in the past years and has transformed itself into a leading contract manufacturer of clinical trial material and for market supply of drug products ranging from low-dose cytokines to higher-dose antibodies and biosimilars.
Rentschler is now marking this transformation with a new campaign.
During the past five years, production capacities have been increased.
Among other new systems, a 1,000 L multi-product disposable facility has been commissioned that was recently recognized with the prestigious Facility of the Year Award (FOYA) in the category Equipment Innovation. More than 300 new jobs have been created.
Dr. Nikolaus F. Rentschler, CEO and Owner of Rentschler Biotechnologie comments, "We are delighted to have received the FOYA for expanding our manufacturing facilities. It rewards our competence beyond the project business as the new facilities will allow us to cost efficiently design and build dedicated production facilities for our customers to ensure the market supply of their products."
To reflect the company's transformation, Rentschler has launched a new website to coincide with BIO 2012.
The new slogan 'Connect. Grow. Succeed.' conveys that by contacting (Connect) and collaborating (Grow) with Rentschler, a successful project outcome (Succeed) will be achieved.
Thus, the slogan summarizes the main advantages and benefits for the customer in a nutshell.
Rentschler has a very successful track record spanning more than three decades.
The company operates nine independent GMP suites comprising stainless steel bioreactors ranging from 30 L to 2,500 L and two 1,000 L single-use systems.
Research Team Discovers Compound that Stops Cancer From SpreadingNews
Using a mouse model, OHSU physician-scientists lead effort to hone a drug that inhibits cancer cells from spreading to other areas in the body.READ MORE
PhoreMost and o2h Discovery Collaborate to Progress First-in-Class Drug Discovery ProgramsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, announced it has entered into a collaboration with o2h discovery (o2h), an Anglo-Indian medicinal chemistry company that has in-house capability to take drug discovery programmes to the IND filing stage.READ MORE
Sartorius Stedim Biotech and Siemens Sign Automation AgreementNews
Siemens becomes a preferred supplier for automation solutions. Product portfolio of Sartorius Stedim Biotech to feature a globally standardized automation platform in the future.READ MORE